On the public citation graph

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update

0 signed · 562 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jama.2009.1232openalex-snapshot
Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy
inferredcites →https://doi.org/10.1001/jama.2010.1543openalex-snapshot
Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI
inferredcites →https://doi.org/10.1001/jama.2011.1703openalex-snapshot
Dosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular Disease
inferredcites →https://doi.org/10.1001/jama.2020.12443openalex-snapshot
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention
inferredcites →https://doi.org/10.1001/jamainternmed.2018.0783openalex-snapshot
Trends in Platelet Adenosine Diphosphate P2Y 12 Receptor Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After Percutaneous Coronary Intervention, 2008-2016
inferredcites →https://doi.org/10.1002/cpt.1911openalex-snapshot
Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium
inferredcites →https://doi.org/10.1002/cpt.1973openalex-snapshot
PharmVar GeneFocus: CYP2C19
inferredcites →https://doi.org/10.1002/cpt.2039openalex-snapshot
Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
inferredcites →https://doi.org/10.1002/cpt.401openalex-snapshot
Exome sequencing of extreme clopidogrel response phenotypes identifies B4GALT2 as a determinant of on‐treatment platelet reactivity
inferredcites →https://doi.org/10.1002/humu.23855openalex-snapshot
Structural variation at the CYP2C locus: Characterization of deletion and duplication alleles
inferredcites →https://doi.org/10.1002/jcph.293openalex-snapshot
Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers
inferredcites →https://doi.org/10.1016/j.amjcard.2015.02.049openalex-snapshot
Contemporary Use of Ticagrelor in Interventional Practice (from Blue Cross Blue Shield of Michigan Cardiovascular Consortium)
inferredcites →https://doi.org/10.1016/j.cjca.2014.09.011openalex-snapshot
Increased Uptake of Guideline-Recommended Oral Antiplatelet Therapy: Insights from the Canadian Acute Coronary Syndrome Reflective
inferredcites →https://doi.org/10.1016/j.jcin.2017.07.022openalex-snapshot
Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
inferredcites →https://doi.org/10.1016/j.jcin.2020.01.226openalex-snapshot
Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel
inferredcites →https://doi.org/10.1016/j.jcin.2021.01.024openalex-snapshot
Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y12 Inhibitor Therapy
inferredcites →https://doi.org/10.1016/j.jmoldx.2018.01.011openalex-snapshot
Recommendations for Clinical CYP2C19 Genotyping Allele Selection
inferredcites →https://doi.org/10.1016/j.thromres.2014.12.007openalex-snapshot
Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention– a systematic review and meta-analysis
inferredcites →https://doi.org/10.1016/s0140-6736(10)61274-3openalex-snapshot
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial
inferredcites →https://doi.org/10.1016/s0140-6736(20)30325-1openalex-snapshot
Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial
inferredcites →https://doi.org/10.1016/s0140-6736(21)00533-xopenalex-snapshot
Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis
inferredcites →https://doi.org/10.1016/s0734-3299(10)79363-1openalex-snapshot
Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes
inferredcites →https://doi.org/10.1038/clpt.2013.105openalex-snapshot
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
inferredcites →https://doi.org/10.1056/nejmoa0706482openalex-snapshot
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
inferredcites →https://doi.org/10.1056/nejmoa0904327openalex-snapshot
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
inferredcites →https://doi.org/10.1056/nejmoa1907096openalex-snapshot
A Genotype-Guided Strategy for Oral P2Y 12 Inhibitors in Primary PCI
inferredcites →https://doi.org/10.1056/nejmoa2111749openalex-snapshot
Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA
inferredcites →https://doi.org/10.1080/09537104.2017.1413178openalex-snapshot
CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in clopidogrel-treated Asian populations: A systematic review and meta-analysis
inferredcites →https://doi.org/10.1093/ehjcvp/pvz045openalex-snapshot
Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients
inferredcites →https://doi.org/10.1093/eurheartj/ehaa575openalex-snapshot
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
inferredcites →https://doi.org/10.1111/j.1538-7836.2010.03921.xopenalex-snapshot
Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy
inferredcites →https://doi.org/10.1111/jth.12342openalex-snapshot
The CYP2C19*17 variant is not independently associated with clopidogrel response
inferredcites →https://doi.org/10.1124/dmd.109.029132openalex-snapshot
Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite
inferredcites →https://doi.org/10.1160/th15-12-0981openalex-snapshot
Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel
inferredcites →https://doi.org/10.1161/cir.0000000000000134openalex-snapshot
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
inferredcites →https://doi.org/10.1161/cir.0b013e31823ba622openalex-snapshot
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
inferredcites →https://doi.org/10.1161/circgenetics.114.000669openalex-snapshot
CYP2C19 Genotype Has a Greater Effect on Adverse Cardiovascular Outcomes Following Percutaneous Coronary Intervention and in Asian Populations Treated With Clopidogrel
inferredcites →https://doi.org/10.1161/circinterventions.118.007434openalex-snapshot
Use of Prasugrel and Ticagrelor in Stable Ischemic Heart Disease After Percutaneous Coronary Intervention, 2009–2016
inferredcites →https://doi.org/10.1161/circinterventions.120.009434openalex-snapshot
Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype
inferredcites →https://doi.org/10.1161/circulationaha.109.851949openalex-snapshot
Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel
inferredcites →https://doi.org/10.1161/circulationaha.109.885194openalex-snapshot
Cytochrome 2C19*17 Allelic Variant, Platelet Aggregation, Bleeding Events, and Stent Thrombosis in Clopidogrel-Treated Patients With Coronary Stent Placement
inferredcites →https://doi.org/10.1161/circulationaha.116.024913openalex-snapshot
Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack
inferredcites →https://doi.org/10.15829/1560-4071-2021-4418openalex-snapshot
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4652646openalex-extracted
Systemic Platelet Inhibition with Localized Chemotherapy via an Injectable ROS-Scavenging Gel Against Postsurgical Breast Cancer Recurrence and Metastasis
inferred← citeshttps://doi.org/10.2139/ssrn.4658568openalex-extracted
Shexiang Tongxin Dropping Pill Ameliorates Microvascular Damage via Reducing ALOX12 After Heart Ischemia-Reperfusion
inferred← citeshttps://doi.org/10.2139/ssrn.4784304openalex-extracted
Shexiang Tongxin Dropping Pill Ameliorates Microvascular Dysfunction Via Downregulating Alox12 after Myocardial Ischemia-Reperfusion
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2023.17037openalex-snapshot
Association of CYP2C19 Loss-of-Function Metabolizer Status With Stroke Risk Among Chinese Patients Treated With Ticagrelor-Aspirin vs Clopidogrel-Aspirin
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2023.8585openalex-snapshot
Assessing the Clinical Treatment Dynamics of Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention in the US
inferred← citeshttps://doi.org/10.1001/jamasurg.2025.1503openalex-snapshot
Drug-Gene Interactions and Clinical Outcomes After Vascular Surgery in the Million Veteran Program
inferred← citeshttps://doi.org/10.1002/1545-5017.70507openalex-snapshot
Bleeding and Thromboembolic Events With Antiplatelet Agents in Pediatric Heart Disease—An Exploratory Study of the Role of Pharmacogenomics
inferred← citeshttps://doi.org/10.1002/9781394180486.ch23openalex-snapshot
Pharmacogenomics
inferred← citeshttps://doi.org/10.1002/advs.202206343openalex-snapshot
Unlocking Genetic Profiles with a Programmable DNA‐Powered Decoding Circuit
inferred← citeshttps://doi.org/10.1002/bcp.70370openalex-snapshot
CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)
inferred← citeshttps://doi.org/10.1002/bcp.70631openalex-snapshot
Evaluation of a pantoprazole and 4‐desmethylpantoprazole‐sulfate metabolic ratio as a novel CYP2C19 phenotyping method
inferred← citeshttps://doi.org/10.1002/bcp.70635openalex-snapshot
Impaired clopidogrel activation due to CYP2C19 phenoconversion after mild acute ischaemic stroke
inferred← citeshttps://doi.org/10.1002/bcp.70722openalex-snapshot
Exposure to CYP2C19‐metabolized drugs following acute stroke: A longitudinal cohort study to inform implementation of CYP2C19 genotype testing
inferred← citeshttps://doi.org/10.1002/bmc.6018openalex-snapshot
Herb–drug interaction study of Yiqi Fumai lyophilized injection (YQFM) on pharmacokinetics of aspirin, nifedipine, and clopidogrel in rats
inferred← citeshttps://doi.org/10.1002/ccd.70794openalex-snapshot
State of the Art: Personalized Antiplatelet Therapy by Genotype and Platelet Function Testing
inferred← citeshttps://doi.org/10.1002/cph4.70027openalex-snapshot
Hepatic Cytochrome P450 Enzymatic System Interaction With Platelet Function and Cardiovascular Outcomes—Pharmacogenomic Impact on Inter‐Organ Communication
inferred← citeshttps://doi.org/10.1002/cpt.2612openalex-snapshot
Impact of the ABCD‐GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multi‐Site, Real‐World Investigation
inferred← citeshttps://doi.org/10.1002/cpt.2776openalex-snapshot
Evaluation of Potential Racial Disparities inCYP2C19‐Guided P2Y12Inhibitor Prescribing After Percutaneous Coronary Intervention
inferred← citeshttps://doi.org/10.1002/cpt.2957openalex-snapshot
An Introductory Tutorial on Cardiovascular Pharmacogenetics for Healthcare Providers
inferred← citeshttps://doi.org/10.1002/cpt.3012openalex-snapshot
Impact of CYP2C:TG Haplotype on CYP2C19 Substrates Clearance In Vivo, Protein Content, and In Vitro Activity
inferred← citeshttps://doi.org/10.1002/cpt.3026openalex-snapshot
High Platelet Reactivity Combined with CYP2C19 Genotype in Predicting Outcomes in East Asian Patients Undergoing Percutaneous Coronary Intervention
inferred← citeshttps://doi.org/10.1002/cpt.3028openalex-snapshot
CYP2C19 Loss‐of‐Function Variants Associated With Long‐Term Ischemic Stroke Events During Clopidogrel Treatment in the Chinese Population
inferred← citeshttps://doi.org/10.1002/cpt.3051openalex-snapshot
Clinician Response to Pharmacogenetic Clinical Decision Support Alerts
inferred← citeshttps://doi.org/10.1002/cpt.3067openalex-snapshot
Ticagrelor Increases Exposure to the Breast Cancer Resistance Protein Substrate Rosuvastatin
inferred← citeshttps://doi.org/10.1002/cpt.3309openalex-snapshot
Mapping the Pharmacogenetic Landscape in a Ugandan Population: Implications for Personalized Medicine in an Underrepresented Population
inferred← citeshttps://doi.org/10.1002/cpt.3502openalex-snapshot
French‐Speaking Network of Pharmacogenetics ( RNPGx ) Recommendations for Clinical Use of Mavacamten
inferred← citeshttps://doi.org/10.1002/cpt.3537openalex-snapshot
Impact of CYP2C19 Phenotype on Escitalopram Response in Geriatrics: Based on Physiologically‐Based Pharmacokinetic Modeling and Clinical Observation
inferred← citeshttps://doi.org/10.1002/cpt.3552openalex-snapshot
Investigation of Genomic and Transcriptomic Risk Factors of Clopidogrel Response in African Americans
inferred← citeshttps://doi.org/10.1002/cpt.3698openalex-snapshot
Evaluation of CYP2C19 Clinical Decision Support Alerts to Guide P2Y12 Inhibitor Prescribing
inferred← citeshttps://doi.org/10.1002/cpt.3707openalex-snapshot
Impact of CYP2C19 Genotype on Sertraline and Escitalopram Exposure and Antidepressant Switching Rate: A Retrospective Cohort Study of Chinese Han Patients
inferred← citeshttps://doi.org/10.1002/cpt.3741openalex-snapshot
CYP2C19 Polymorphisms and Clinical Outcomes Following Percutaneous Coronary Intervention in the Million Veteran Program
inferred← citeshttps://doi.org/10.1002/cpt.70005openalex-snapshot
Advancing Clinical Pharmacogenomics Worldwide Through the Clinical Pharmacogenetics Implementation Consortium ( CPIC )
inferred← citeshttps://doi.org/10.1002/cpt.70083openalex-snapshot
Clinical Implementation of Pharmacogenomics and Drug–Drug Interaction Screening in a German Academic Teaching Hospital and Outpatient Follow‐Up
inferred← citeshttps://doi.org/10.1002/cpt.70154openalex-snapshot
Prognostic Implication of CYP2C19 Genotype According to Clinical Risk Stratification After Drug‐Eluting Stent Implantation
inferred← citeshttps://doi.org/10.1002/cpt.70248openalex-snapshot
Pharmacogenetics—Not Just Low‐Hanging Fruit
inferred← citeshttps://doi.org/10.1002/cpt.70269openalex-snapshot
The Burden of Adverse Drug Reactions in Africa in the Context of Pharmacogenetics‐Based Clinical Guidelines
inferred← citeshttps://doi.org/10.1002/cpt.70271openalex-snapshot
Community Partnerships in Clinical Research: A Framework for Sustainability and Resilience
inferred← citeshttps://doi.org/10.1002/cpt.70338openalex-snapshot
Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention
inferred← citeshttps://doi.org/10.1002/cpt.70402openalex-snapshot
CYP2C19 Genotyping to Guide Clopidogrel Prescribing for Neurovascular Indications: A Survey of Institutional Approaches
inferred← citeshttps://doi.org/10.1002/cpt.70504openalex-snapshot
Implementation of Rapid CYP2C19 Genotyping to Guide Antiplatelet Therapy for Secondary Prevention of Ischemic Stroke and Transient Ischemic Attack
inferred← citeshttps://doi.org/10.1002/ctd2.296openalex-snapshot
GWAS advancements to investigate disease associations and biological mechanisms
inferred← citeshttps://doi.org/10.1002/dad2.70423openalex-snapshot
Pharmacogenetic analyses in people with dementia in Northeast Germany
inferred← citeshttps://doi.org/10.1002/ddr.70093openalex-snapshot
Optimizing Treatment: The Role of Pharmacology, Genomics, and AI in Improving Patient Outcomes
inferred← citeshttps://doi.org/10.1002/jac5.1928openalex-snapshot
Here is my sequence: The pharmacist's role in interpreting pharmacogenomic results
inferred← citeshttps://doi.org/10.1002/jac5.1958openalex-snapshot
Decoding pharmacogenomic test interpretation and application to patient care
inferred← citeshttps://doi.org/10.1002/jac5.2057openalex-snapshot
The impact of pharmacogenomics on a pharmacy and therapeutic committee's formulary system management: An opinion of the pharmacokinetics/pharmacodynamics/pharmacogenomics practice and Research Network for the American College of Clinical Pharmacy
inferred← citeshttps://doi.org/10.1002/jcla.70088openalex-snapshot
CYP2C19 Loss‐of‐Function Is an Independent Risk Factor of Coronary Artery Disease in Patients With Hypertension
inferred← citeshttps://doi.org/10.1002/mgg3.70201openalex-snapshot
Pharmacogenomic Calling From Whole‐Exome Sequencing in the Taiwanese Population—A Real‐World Experience
inferred← citeshttps://doi.org/10.1002/phar.2758openalex-snapshot
Pharmacogenetics of P2Y 12 receptor inhibitors
inferred← citeshttps://doi.org/10.1002/phar.2798openalex-snapshot
Pharmacogenomics and beyond! Customized pharmacotherapy for solid organ transplant recipients
inferred← citeshttps://doi.org/10.1002/phar.70201openalex-snapshot
Association Between CYP2C19 Genotype and P2Y12 Reaction Units in Patients Receiving Clopidogrel After Acute Ischemic Stroke: A Prospective, Observational Study
inferred← citeshttps://doi.org/10.1002/psp4.13053openalex-snapshot
Population pharmacokinetic‐pharmacodynamic modeling of clopidogrel for dose regimen optimization based on CYP2C19 phenotypes: A proof of concept study
inferred← citeshttps://doi.org/10.1007/978-1-4939-0779-3_136-2openalex-snapshot
Pharmacogenomics Implementation in Family Medicine
inferred← citeshttps://doi.org/10.1007/978-3-030-73317-9_110-1openalex-snapshot
Pharmacogenomics in Drug Metabolism Enzymes and Transporters
inferred← citeshttps://doi.org/10.1007/978-3-031-29171-5_1openalex-snapshot
Genetic Contributions and Personalized Medicine
inferred← citeshttps://doi.org/10.1007/978-3-031-35529-5_110openalex-snapshot
Pharmacogenomics in Drug Metabolism Enzymes and Transporters
inferred← citeshttps://doi.org/10.1007/978-3-032-10653-7_5openalex-snapshot
Pharmacogenomics and Cardiovascular Care for Older Adults
inferred← citeshttps://doi.org/10.1007/978-3-032-34362-8_9openalex-snapshot
Consequences of Homogeneity
inferred← citeshttps://doi.org/10.1007/978-981-99-1284-1_19openalex-snapshot
Impact of Genetic Variation on Drug Response
inferred← citeshttps://doi.org/10.1007/s00228-023-03519-yopenalex-snapshot
The contribution of genotype-guided selection of P2Y12 inhibitor on prognosis in ACS /CCS patients undergoing percutaneous coronary intervention: a retrospective cohort study
inferred← citeshttps://doi.org/10.1007/s00228-023-03522-3openalex-snapshot
Long-term effectiveness and safety of cilostazol versus clopidogrel in secondary prevention of noncardioembolic ischemic stroke
inferred← citeshttps://doi.org/10.1007/s00228-025-03991-8openalex-snapshot
CYP2C19 genotyping and mavacamten: predicting outcomes in normal, intermediate and rapid metabolisers in obstructive hypertrophic cardiomyopathy
inferred← citeshttps://doi.org/10.1007/s00228-026-03998-9openalex-snapshot
Clinical pharmacology of antiplatelet drugs: implications for personalized therapy
inferred← citeshttps://doi.org/10.1007/s00228-026-04173-wopenalex-snapshot
Recent research progress on the mechanisms of clopidogrel resistance
inferred← citeshttps://doi.org/10.1007/s00280-026-04926-5openalex-snapshot
Design characteristics of mass balance studies conducted for protein kinase inhibitors
inferred← citeshttps://doi.org/10.1007/s00604-023-05781-4openalex-snapshot
Electrochemical peptide nucleic acid functionalized α-Fe2O3/Fe3O4 nanosheets for detection of CYP2C19*2 gene
inferred← citeshttps://doi.org/10.1007/s10557-023-07534-0openalex-snapshot
Impact of CYP2C19 Genotype on Efficacy and Safety of Clopidogrel-based Antiplatelet Therapy in Stroke or Transient Ischemic Attack Patients: An Updated Systematic Review and Meta-analysis of Non-East Asian Studies
inferred← citeshttps://doi.org/10.1007/s10557-024-07544-6openalex-snapshot
The Impact of CYP2C19 Genotype on the Platelet Reactivity Index (PRI) among Chronic Coronary Syndromes (CCS) Patients Undergoing Percutaneous Coronary Intervention (PCI): Affectability of Rapid Genetic Testing
inferred← citeshttps://doi.org/10.1007/s10557-024-07627-4openalex-snapshot
CYP2C19 Genotype-Guided Antiplatelet Therapy in Stroke Patients—Is It Ready for Prime Time?
inferred← citeshttps://doi.org/10.1007/s11239-024-02953-8openalex-snapshot
Development of a routine bedside CYP2C19 genotype assessment program for antiplatelet therapy guidance in a community hospital catheterization laboratory
inferred← citeshttps://doi.org/10.1007/s11883-026-01414-2openalex-snapshot
Pharmacogenomics of Atherosclerotic Plaque: Pathophysiological Background and Therapeutic Perspectives
inferred← citeshttps://doi.org/10.1007/s12170-022-00713-yopenalex-snapshot
Application of Pharmacogenetics for the Use of Antiplatelet and Anticoagulant Drugs
inferred← citeshttps://doi.org/10.1007/s12181-024-00679-8openalex-snapshot
Komorbiditäten bei Herzerkrankungen – Ausmaß und Folgen
inferred← citeshttps://doi.org/10.1007/s12181-026-00821-8openalex-snapshot
Umstellung antithrombozytärer Therapien: Interaktionen und praktische Durchführung – DGK-Empfehlung
inferred← citeshttps://doi.org/10.1007/s12288-025-02200-xopenalex-snapshot
Association of Cyp2c19 Genotype with Variability in Clopidogrel Response in Coronary Patients
inferred← citeshttps://doi.org/10.1007/s12687-026-00914-7openalex-snapshot
A primary care pharmacogenetic precision medicine pilot based on specific Māori tribal ethical frameworks and principles
inferred← citeshttps://doi.org/10.1007/s40119-024-00348-7openalex-snapshot
Prevalence of CYP2C19*2 and CYP2C19*3 Allelic Variants and Clopidogrel Use in Patients with Cardiovascular Disease in Trinidad & Tobago
inferred← citeshttps://doi.org/10.1007/s40265-024-02076-7openalex-snapshot
Impact of CYP2C19 Genotype Status on Clinical Outcomes in Patients with Symptomatic Coronary Artery Disease, Stroke, and Peripheral Arterial Disease: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.1007/s40273-026-01586-4openalex-snapshot
Economic Evaluation of Pre-emptive Pharmacogenetic Panel Testing versus No Genetic Testing in a Multi-ethnic Asian Population
inferred← citeshttps://doi.org/10.1016/b978-0-443-16013-4.00010-5openalex-snapshot
Applications of molecular pharmacology in drug discovery
inferred← citeshttps://doi.org/10.1016/b978-0-443-26472-6.00022-xopenalex-snapshot
Implementation of Pharmacogenomics in Clinical Pharmacy Practice
inferred← citeshttps://doi.org/10.1016/b978-0-443-26472-6.00063-2openalex-snapshot
Pharmacogenomics in the Community Setting
inferred← citeshttps://doi.org/10.1016/b978-0-443-26472-6.00165-0openalex-snapshot
Pharmacogenomics in Hospital Practice: Implementation, Clinical Applications and Future Perspectives
inferred← citeshttps://doi.org/10.1016/b978-0-443-28830-2.00010-5openalex-snapshot
Tryptamine interfere with cytochrome P450
inferred← citeshttps://doi.org/10.1016/b978-0-443-29289-7.00018-7openalex-snapshot
Drug metabolism in cardiovascular disease
inferred← citeshttps://doi.org/10.1016/b978-0-443-44415-9.00013-2openalex-snapshot
AI-powered genomic medicine: Technologies and challenges
inferred← citeshttps://doi.org/10.1016/j.actbio.2024.01.037openalex-snapshot
Systemic platelet inhibition with localized chemotherapy by an injectable ROS-scavenging gel against postsurgical breast cancer recurrence and metastasis
inferred← citeshttps://doi.org/10.1016/j.actpha.2022.03.009openalex-snapshot
Apport de la pharmacogénétique dans le domaine cardio-vasculaire, l’exemple des statines
inferred← citeshttps://doi.org/10.1016/j.ahj.2024.10.017openalex-snapshot
Efficacy of dual antiplatelet therapy after ischemic stroke according to hsCRP levels and CYP2C19 genotype
inferred← citeshttps://doi.org/10.1016/j.ahj.2025.02.020openalex-snapshot
Genotype-guided de-escalation and abbreviation of dual antiplatelet therapy in patients with myocardial infarction and high bleeding risk: Design and rationale of the investigator-initiated, multicenter, randomized, controlled trial, DAN-DAPT
inferred← citeshttps://doi.org/10.1016/j.ajhg.2025.09.006openalex-snapshot
Local ancestry-informed GWAS of warfarin dose requirement in African Americans identifies a CYP2C19 splicing QTL
inferred← citeshttps://doi.org/10.1016/j.amjcard.2023.06.090openalex-snapshot
Rates of 30-Day and 90-Day Readmission Between Genotype-Optimal and Genotype-Suboptimal Antiplatelet Therapy Prescribing After Percutaneous Coronary Intervention
inferred← citeshttps://doi.org/10.1016/j.bcp.2024.116249openalex-snapshot
Pharmacogene expression during progression of metabolic dysfunction-associated steatotic liver disease: Studies on mRNA and protein levels and their relevance to drug treatment
inferred← citeshttps://doi.org/10.1016/j.bcp.2025.116809openalex-snapshot
Interactions between the intestinal microbiota and drug metabolism – Clinical implications and future opportunities
inferred← citeshttps://doi.org/10.1016/j.bcp.2025.117330openalex-snapshot
Promising clopidogrel analogs may overcome clopidogrel resistance: 2025 update
inferred← citeshttps://doi.org/10.1016/j.bioorg.2025.109009openalex-snapshot
Antiplatelet therapy through inhibition of P2Y12 and phosphodiesterase receptors by novel synthesis 1,3-dicyclohexylpyrimidine-2,4(1H,3H)-dione derivatives with computational evaluation
inferred← citeshttps://doi.org/10.1016/j.bios.2025.117760openalex-snapshot
Single-tube Lambda exonuclease-mediated LbuCas13a detect of ssDNA for single-nucleotide polymorphisms genotyping
inferred← citeshttps://doi.org/10.1016/j.bios.2026.119263openalex-snapshot
A CRISPR/Cas14a-based platform for sensitive and specific single-nucleotide variant detection via short single-strand DNA amplification and split target design
inferred← citeshttps://doi.org/10.1016/j.bulcan.2025.04.014openalex-snapshot
Anticipation des problèmes pharmacothérapeutiques en amont de l’allogreffe (SFGM-TC)
inferred← citeshttps://doi.org/10.1016/j.clineuro.2026.109385openalex-snapshot
A multidimensional study of antiplatelet therapy and CYP2C19 genetic testing in patients with ischemic stroke and transient ischemic attack
inferred← citeshttps://doi.org/10.1016/j.clinthera.2024.06.019openalex-snapshot
Pharmacogenomic Polygenic Model of Clopidogrel Predicts Recurrent Ischemic Events in Chinese Patients With Coronary Artery Disease
inferred← citeshttps://doi.org/10.1016/j.clinthera.2025.03.003openalex-snapshot
Aspirin Plus Clopidogrel Reduces Infection Risk Compared With Aspirin or Clopidogrel Alone in Acute Ischemic Stroke
inferred← citeshttps://doi.org/10.1016/j.clinthera.2025.12.003openalex-snapshot
Implementing CYP2C19 Pharmacogenetic Testing for Personalized Antiplatelet Therapy: Findings From the QPGx-CARES Initiative
inferred← citeshttps://doi.org/10.1016/j.clinthera.2026.02.002openalex-snapshot
Response to Letter to the Editor: Commending the Feasibility of CYP2C19 Pharmacogenetic Testing in Personalized Antiplatelet Therapy—Insights and Perspectives
inferred← citeshttps://doi.org/10.1016/j.cnur.2024.12.007openalex-snapshot
The Use of Pharmacogenomics in Cardiovascular Care
inferred← citeshttps://doi.org/10.1016/j.cnur.2025.01.006openalex-snapshot
Pharmacogenomics for Nurses
inferred← citeshttps://doi.org/10.1016/j.cobme.2025.100592openalex-snapshot
Diversity in a dish: Leveraging organoids to reflect genetic ancestry and sex differences in health and disease
inferred← citeshttps://doi.org/10.1016/j.cpha.2022.10.013openalex-snapshot
What Is Precision Medicine?
inferred← citeshttps://doi.org/10.1016/j.cvsm.2023.05.016openalex-snapshot
The Role of Personalized Medicine in Companion Animal Cardiology
inferred← citeshttps://doi.org/10.1016/j.ecoenv.2025.119444openalex-snapshot
Developmental reprogramming of cytochrome P450 enzymes in offspring by adverse maternal factors exposure: Implications for long-term metabolic disease susceptibility
inferred← citeshttps://doi.org/10.1016/j.ejmech.2025.117973openalex-snapshot
Discovery of a novel and potent antiplatelet thiol prodrug CG-0255
inferred← citeshttps://doi.org/10.1016/j.ejps.2022.106264openalex-snapshot
Semi-mechanistic population pharmacokinetics analysis reveals distinct CYP2C19 dependency in the bioactivation of vicagrel and clopidogrel to active metabolite M15–2
inferred← citeshttps://doi.org/10.1016/j.forsciint.2025.112445openalex-snapshot
The Impact of CYP2D6 metabolizer phenotypes on the EDDP/methadone metabolic ratio: A comprehensive analysis
inferred← citeshttps://doi.org/10.1016/j.gene.2025.149935openalex-snapshot
Bioinformatics applications in pharmacogenomics: towards personalized medicine
inferred← citeshttps://doi.org/10.1016/j.gimo.2025.103441openalex-snapshot
Implementation of genetic testing for heritable cardiac conditions: A scoping review
inferred← citeshttps://doi.org/10.1016/j.heliyon.2023.e22214openalex-snapshot
Advances and Perspectives in methods for identifying high platelet reactivity
inferred← citeshttps://doi.org/10.1016/j.heliyon.2024.e28566openalex-snapshot
Genetic polymorphisms of CYP2C19 in ecuadorian population: An interethnic approach
inferred← citeshttps://doi.org/10.1016/j.heliyon.2024.e31383openalex-snapshot
Evaluation of the efficacy of Wall Shear Stress in Carotid Artery Stenting
inferred← citeshttps://doi.org/10.1016/j.hfc.2025.09.002openalex-snapshot
Genetic Determinants of Response to P2Y12 Inhibitors and Clinical Implications
inferred← citeshttps://doi.org/10.1016/j.iccl.2024.06.002openalex-snapshot
Genetic Determinants of Response to P2Y12 Inhibitors and Clinical Implications
inferred← citeshttps://doi.org/10.1016/j.ijcard.2024.132481openalex-snapshot
Shexiang Tongxin dropping pill ameliorates microvascular obstruction via downregulating ALOX12 after myocardial ischemia-reperfusion
inferred← citeshttps://doi.org/10.1016/j.ijcrp.2023.200222openalex-snapshot
The combination of CYP2C19 polymorphism and inflammatory cell ratios in prognosis cardiac adverse events after acute coronary syndrome
inferred← citeshttps://doi.org/10.1016/j.jacadv.2023.100573openalex-snapshot
CYP2C19 Genotype Prevalence and Association With Recurrent Myocardial Infarction in British–South Asians Treated With Clopidogrel
inferred← citeshttps://doi.org/10.1016/j.jacasi.2025.08.002openalex-snapshot
CYP2C19 Genotype–Guided Antiplatelet Therapy in Precision Medicine for Stroke
inferred← citeshttps://doi.org/10.1016/j.jacasi.2025.10.028openalex-snapshot
Revisiting the Proton Pump Inhibitor–Clopidogrel Conundrum
inferred← citeshttps://doi.org/10.1016/j.jacc.2024.02.015openalex-snapshot
Effectiveness of Clopidogrel vs Alternative P2Y12 Inhibitors Based on the ABCD-GENE Score
inferred← citeshttps://doi.org/10.1016/j.jacc.2024.06.038openalex-snapshot
Genotype-Guided Antiplatelet Therapy
inferred← citeshttps://doi.org/10.1016/j.jccase.2023.08.011openalex-snapshot
Instant subacute stent thrombosis after maximum-load cardiopulmonary exercise test in a clopidogrel poor metabolizer with acute coronary syndrome
inferred← citeshttps://doi.org/10.1016/j.jcin.2023.01.363openalex-snapshot
Clinical Impact of CYP2C19 Genotype on Clopidogrel-Based Antiplatelet Therapy After Percutaneous Coronary Intervention
inferred← citeshttps://doi.org/10.1016/j.jcin.2023.02.021openalex-snapshot
Genotype-Guided Selection of Antiplatelet Therapy
inferred← citeshttps://doi.org/10.1016/j.jcin.2024.03.027openalex-snapshot
P2Y12 Inhibition in Patients Requiring Oral Anticoagulation After Percutaneous Coronary Intervention
inferred← citeshttps://doi.org/10.1016/j.jcin.2024.07.014openalex-snapshot
Genotype-Guided De-Escalation of DAPT
inferred← citeshttps://doi.org/10.1016/j.jcin.2024.08.027openalex-snapshot
International Consensus Statement on Platelet Function and Genetic Testing in Percutaneous Coronary Intervention
inferred← citeshttps://doi.org/10.1016/j.jcin.2025.11.029openalex-snapshot
Genotype-Guided vs Conventional Oral P2Y12 Inhibitors in Acute Coronary Syndrome
inferred← citeshttps://doi.org/10.1016/j.jmoldx.2024.12.001openalex-snapshot
Development and Validation of a Rapid Point-of-Care CYP2C19 Genotyping Platform
inferred← citeshttps://doi.org/10.1016/j.jns.2026.125813openalex-snapshot
Authors' response to reviewers' comments on “Effectiveness and safety of prasugrel- versus clopidogrel-based dual antiplatelet therapy for acute ischemic stroke”
inferred← citeshttps://doi.org/10.1016/j.jocn.2025.111745openalex-snapshot
Dual antiplatelet therapy guided by CYP2C19 polymorphism after intracranial or extracranial stenting: A single-center retrospective cohort study
inferred← citeshttps://doi.org/10.1016/j.jstrokecerebrovasdis.2024.107684openalex-snapshot
Factors associated with clopidogrel resistance and clinical outcomes in ischemic cerebrovascular disease: A retrospective study
inferred← citeshttps://doi.org/10.1016/j.jtha.2023.09.013openalex-snapshot
Antiplatelet strategies: past, present, and future
inferred← citeshttps://doi.org/10.1016/j.jvs.2025.10.101openalex-snapshot
A systematic review and meta-analysis of the impact of clopidogrel responsiveness on ischemic and bleeding complications after noncoronary endovascular procedures
inferred← citeshttps://doi.org/10.1016/j.jvsvi.2024.100112openalex-snapshot
A review of clopidogrel resistance in lower extremity arterial disease
inferred← citeshttps://doi.org/10.1016/j.jvsvi.2026.100529openalex-snapshot
CYP2C19 loss-of-function carriers have increased risk of cardiac, but not limb, events following clopidogrel treatment for peripheral artery disease revascularization
inferred← citeshttps://doi.org/10.1016/j.lanwpc.2023.100779openalex-snapshot
Association between genetic predisposition and disease burden of stroke in China: a genetic epidemiological study
inferred← citeshttps://doi.org/10.1016/j.mayocp.2024.10.016openalex-snapshot
When Patients Present With Direct-to-Consumer Pharmacogenomic Test Results
inferred← citeshttps://doi.org/10.1016/j.mpsur.2025.02.001openalex-snapshot
The impact of cancer genomics across the surgical pathway
inferred← citeshttps://doi.org/10.1016/j.pec.2023.107904openalex-snapshot
Patient understanding of pharmacogenomic test results in clinical care
inferred← citeshttps://doi.org/10.1016/j.pharmr.2026.100122openalex-snapshot
The evolving landscape of pharmacogenomics: Current achievements and future directions
inferred← citeshttps://doi.org/10.1016/j.pharmr.2026.100136openalex-snapshot
Pharmacogenomics of antibacterial and antiviral therapies: Clinical actionability, evidence gaps, and future directions
inferred← citeshttps://doi.org/10.1016/j.pharmthera.2025.108929openalex-snapshot
Mass spectrometry-based absolute quantitative proteomics of drug-metabolizing enzymes in human liver
inferred← citeshttps://doi.org/10.1016/j.placenta.2023.04.019openalex-snapshot
Effects of genetic polymorphisms of CYP2J2, CYP2C9, CYP2C19, CYP4F2, CYP4F3 and CYP4A11 enzymes in preeclampsia and gestational hypertension
inferred← citeshttps://doi.org/10.1016/j.prmedi.2024.10.001openalex-snapshot
Current status and prospects of nucleic acid mass spectrometry in clinical pharmacogenomics
inferred← citeshttps://doi.org/10.1016/j.prp.2025.156280openalex-snapshot
Next generation DNA sequencing data analysis and its application in clinical genomics
inferred← citeshttps://doi.org/10.1016/j.radcr.2023.09.107openalex-snapshot
Iatrogenic intramuscular hematoma of the oblique muscles as a complication of technetium-99m-labeled pyrophosphate imaging-based computed tomography-guided core-needle biopsy in a patient with wild-type transthyretin cardiac amyloidosis
inferred← citeshttps://doi.org/10.1016/j.radcr.2024.03.038openalex-snapshot
Management of ruptured aneurysmal subarachnoid hemorrhage with multiple basilar trunk aneurysms using a flow-diverter stent: A case report
inferred← citeshttps://doi.org/10.1016/j.rcsop.2026.100830openalex-snapshot
In defence of the drug, two hearts, one profession: Reintegrating medicines expertise and patient-centred care in pharmacy's professional identity
inferred← citeshttps://doi.org/10.1016/j.rpth.2023.100138openalex-snapshot
Precision antiplatelet therapy
inferred← citeshttps://doi.org/10.1016/j.rpth.2025.102997openalex-snapshot
Efficacy and safety of clopidogrel and ticagrelor in acute coronary syndrome patients with CYP2C19 loss-of-function alleles after percutaneous coronary intervention: based on the Global Registry of Acute Coronary Events score
inferred← citeshttps://doi.org/10.1016/j.semnephrol.2025.151660openalex-snapshot
Beyond Kidney Genes: Broad Clinical Implications of Genetic Testing for Nephrology Patients
inferred← citeshttps://doi.org/10.1016/j.tcm.2022.11.001openalex-snapshot
Precision medicine: Hype or hope?
inferred← citeshttps://doi.org/10.1016/j.thromres.2024.02.010openalex-snapshot
The effects of CYP2C19 genotype polymorphism and clopidogrel resistance on ischemic event occurrence in patients with peripheral arterial disease undergoing revascularization: A prospective cohort study
inferred← citeshttps://doi.org/10.1016/j.tips.2024.11.005openalex-snapshot
Demographic diversity in platelet function and response to antiplatelet therapy
inferred← citeshttps://doi.org/10.1016/j.vhri.2025.101565openalex-snapshot
Cost-Utility and Budget Impact Analysis of Pharmacogenetic-Guided Antiplatelet Therapy for Acute Coronary Syndrome in Thailand
inferred← citeshttps://doi.org/10.1016/j.xhgg.2022.100100openalex-snapshot
From pharmacogenetics to pharmaco-omics: Milestones and future directions
inferred← citeshttps://doi.org/10.1016/j.yamp.2023.08.004openalex-snapshot
Long-read Sequencing for Germline Pharmacogenomic Testing
inferred← citeshttps://doi.org/10.1017/pcm.2023.17openalex-snapshot
Cardiovascular precision medicine – A pharmacogenomic perspective
inferred← citeshttps://doi.org/10.1017/pcm.2023.17.pr1openalex-snapshot
Author comment: Cardiovascular precision medicine – A pharmacogenomic perspective — R0/PR1
inferred← citeshttps://doi.org/10.1017/pcm.2023.17.pr2openalex-snapshot
Review: Cardiovascular precision medicine – A pharmacogenomic perspective — R0/PR2
inferred← citeshttps://doi.org/10.1017/pcm.2023.17.pr3openalex-snapshot
Recommendation: Cardiovascular precision medicine – A pharmacogenomic perspective — R0/PR3
inferred← citeshttps://doi.org/10.1017/pcm.2023.17.pr4openalex-snapshot
Decision: Cardiovascular precision medicine – A pharmacogenomic perspective — R0/PR4
inferred← citeshttps://doi.org/10.1017/pcm.2023.17.pr5openalex-snapshot
Author comment: Cardiovascular precision medicine – A pharmacogenomic perspective — R1/PR5
inferred← citeshttps://doi.org/10.1017/pcm.2023.17.pr6openalex-snapshot
Review: Cardiovascular precision medicine – A pharmacogenomic perspective — R1/PR6
inferred← citeshttps://doi.org/10.1017/pcm.2023.17.pr7openalex-snapshot
Recommendation: Cardiovascular precision medicine – A pharmacogenomic perspective — R1/PR7
inferred← citeshttps://doi.org/10.1017/pcm.2023.17.pr8openalex-snapshot
Decision: Cardiovascular precision medicine – A pharmacogenomic perspective — R1/PR8
inferred← citeshttps://doi.org/10.1021/acs.analchem.3c01907openalex-snapshot
Precise Differentiation of Wobble-Type Allele via Ratiometric Design of a Ligase Chain Reaction-Based Electrochemical Biosensor for CYP2C19*2 Genotyping of Clinical Samples
inferred← citeshttps://doi.org/10.1021/acs.molpharmaceut.5c00462openalex-snapshot
Confounding Effect of Hepatic Carboxylesterase 1 (CES1) Variability on Clopidogrel Oxidation
inferred← citeshttps://doi.org/10.1021/acssensors.5c01577openalex-snapshot
Constant Temperature Electrochemical Biosensor for SNP Detection in Human Genomic DNA Based on DNA Melting Analysis
inferred← citeshttps://doi.org/10.1021/acssensors.6c00841openalex-snapshot
CRISPR-Based Assay for Point-of-Care Pharmacogenetic CYP2C19 Genotyping
inferred← citeshttps://doi.org/10.1021/acssensors.6c01221openalex-snapshot
Quo Vadis , Electrochemical DNA Biosensor? Lessons from Three Decades of SNP Sensing
inferred← citeshttps://doi.org/10.1038/s41397-022-00278-4openalex-snapshot
Point of care CYP2C19 genotyping after percutaneous coronary intervention
inferred← citeshttps://doi.org/10.1038/s41397-022-00288-2openalex-snapshot
The genetic landscape of major drug metabolizing cytochrome P450 genes—an updated analysis of population-scale sequencing data
inferred← citeshttps://doi.org/10.1038/s41397-025-00371-4openalex-snapshot
Implementing CYP2C19-guided clopidogrel therapy: a scoping review of pharmacogenomic testing services
inferred← citeshttps://doi.org/10.1038/s41397-026-00398-1openalex-snapshot
A functional ancestry-linked regulatory haplotype influences CYP2D6 expression
inferred← citeshttps://doi.org/10.1038/s41397-026-00421-5openalex-snapshot
The association of ABCB1, CYP2C19 and CYP2C9 combined activity with clopidogrel resistance in patients with recurrent ischemic stroke
inferred← citeshttps://doi.org/10.1038/s41398-022-02203-6openalex-snapshot
Barriers to genetic testing in clinical psychiatry and ways to overcome them: from clinicians’ attitudes to sociocultural differences between patients across the globe
inferred← citeshttps://doi.org/10.1038/s41421-023-00582-8openalex-snapshot
The STROMICS genome study: deep whole-genome sequencing and analysis of 10K Chinese patients with ischemic stroke reveal complex genetic and phenotypic interplay
inferred← citeshttps://doi.org/10.1038/s41431-024-01567-1openalex-snapshot
Clinical impact of preemptive pharmacogenomic testing on antiplatelet therapy in a real-world setting
inferred← citeshttps://doi.org/10.1038/s41431-026-02025-wopenalex-snapshot
The potential of whole genome sequencing in pharmacogenetics: a retrospective health record study in rare disease patients
inferred← citeshttps://doi.org/10.1038/s41431-026-02226-3openalex-snapshot
Patient views on receiving a pharmacogenetic passport – a mixed methods study exploring experiences and use after an opportunistic offer
inferred← citeshttps://doi.org/10.1038/s41467-023-37209-1openalex-snapshot
Clinically important alterations in pharmacogene expression in histologically severe nonalcoholic fatty liver disease
inferred← citeshttps://doi.org/10.1038/s41467-024-53556-zopenalex-snapshot
Socio-demographic and genetic risk factors for drug adherence and persistence across 5 common medication classes
inferred← citeshttps://doi.org/10.1038/s41525-024-00403-1openalex-snapshot
A call for increased inclusivity and global representation in pharmacogenetic testing
inferred← citeshttps://doi.org/10.1038/s41525-025-00479-3openalex-snapshot
Discovery of ancestry-specific variants associated with clopidogrel response among Caribbean Hispanics
inferred← citeshttps://doi.org/10.1038/s41525-025-00511-6openalex-snapshot
A narrative review of research advancements in pharmacogenetics of cardiovascular disease and impact on clinical implications
inferred← citeshttps://doi.org/10.1038/s41525-025-00549-6openalex-snapshot
Pharmacokinetic recall study of Estonian Biobank participants with novel genetic variants in CYP2C19 and CYP2D6
inferred← citeshttps://doi.org/10.1038/s41569-026-01249-zopenalex-snapshot
Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapies
inferred← citeshttps://doi.org/10.1038/s41591-025-03558-1openalex-snapshot
Evolution, genetic diversity, and health
inferred← citeshttps://doi.org/10.1038/s41598-025-34150-9openalex-snapshot
Network pharmacology and molecular docking reveal mechanisms of amiodarone-induced pulmonary fibrosis
inferred← citeshttps://doi.org/10.1038/s41598-025-96338-3openalex-snapshot
Integrative pharmacogenomics analysis predicts the platelet response in clopidogrel treated coronary artery disease (CAD) patients of South India
inferred← citeshttps://doi.org/10.1039/d3lc00391dopenalex-snapshot
Rapid microfluidics prototyping through variotherm desktop injection molding for multiplex diagnostics
inferred← citeshttps://doi.org/10.1039/d4ra03913kopenalex-snapshot
Convenient two-step method constructed silicon-based microfluidic chip for fast CYP2C19 SNPs detection
showing the first 200 of 519 · page through all 519
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.